Neonatal Gene Therapy Confers Years-Long HIV Protection in Primates
A groundbreaking study demonstrates that a single dose of AAV-delivered broadly neutralizing antibodies (bNAbs) administered at birth provides durable HIV protection for over three years in infant primates. The research leverages neonatal immune tolerance to overcome anti-drug antibody challenges that typically limit efficacy in adults, with significant implications for preventing perinatal HIV transmission.